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Purpose: To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication
adherence, while also determining whether or not altering the functionality of the DA in three
randomized subject groups can reduce observer effect.
Methods: Forty-five subjects were randomized into three groups: two with monitored DAs
and one without monitoring. One group of subjects was given a DA that both monitored drop
usage and had visual and audible alarms, while the other monitored group included subjects
given a DA that had no alarms but continued to monitor drop usage. The third group was given
a DA that had no alarm reminders or dose usage monitoring. Subjects were informed that some
monitors would not be functional, in an attempt to reduce observer effect, or the effect of being
monitored on subject behavior and adherence. A six-item questionnaire was also utilized to
assess how the subjects felt about their adherence and DA use.
Results: The overall adherence rates were found to be 78% in the fully functional group
(95% confidence interval: 70–88) and 76% in the no alarms group (95% confidence interval:
65–89). No association was seen between questionnaire response and medication adherence.
The patients in the DA group without alarms had a significantly higher odds ratio of medication adherence if they reported on the questionnaire that using the DA did affect how much
they used their drops.
Conclusion: Though the use of DA was expected to reveal different rates of adherence
depending on the functionality of the DA between groups, patients with a nonfunctioning DA
did not have a significant difference in medication adherence compared to those given a fully
functional DA. This supports that an observer effect was not reduced despite these interventions, and that the subjects adhered to taking their medications as if they had a functioning DA
and were being monitored.
Keywords: dosing aid, observer effect, glaucoma, adherence
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Glaucoma is a chronic, optic neuropathy characterized by optic nerve damage, visual
field defects, elevated intraocular pressure, and progressive vision loss that impacts
60 million people worldwide.1 Glaucoma management typically includes a daily
eyedrop regimen.2,3 When properly used, eyedrop medication can effectively lower
intraocular pressure, reduce optic nerve deterioration, preserve vision, and prevent
glaucomatous blindness. However, rates of medication adherence and persistence
(ie, continued use of medication over time) are especially low among patients diagnosed with glaucoma.4–6 Electronic monitoring of glaucoma medication administration
found that adherence rates were poor.7–9 Okeke et al found that among patients being
provided free medication for once-daily dosing who knew they were being monitored,
45% used their eyedrops less than 75% of the time. Further, close to one fifth of
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Okeke et al’s subjects (19.4%) used eyedrops less than 50%
of the time.6 Prospective randomized trials on the impact of
adherence on clinical outcomes in glaucoma are lacking.
Foucault wrote in his work on prison construction about
the effect of monitoring on behavior.7 Ideally, he suggested,
prisons should be constructed in such a way that monitoring
is possible at all times but that the prisoner should not be able
to tell at what point he is being monitored. He states that if
a prisoner cannot tell whether or not he is being monitored,
he will behave as if he is being monitored at all times. He
coined the term “panopticism” for this effect.7
Clinical trials are performed to guide clinical practice,
but the nature of a clinical trial may include biases that
differ from clinical practice. Observer effect, reactivity,
and “guinea pig” effect are some of the names given to the
way observation influences the behavior of study subjects.
Given that adherence to medications remains an important
issue in medical treatment, 2,3 it is important to explore
the unobserved, or “real”, medication adherence habits of
patients with glaucoma. However, the evolution of ethical
considerations and increasingly strict regulations governing
clinical trials make it inappropriate to collect data on patients
without their knowledge. With these considerations in mind,
we designed a study to assess eyedrop medication adherence
using a Travoprost Dosing Aid (DA), in an attempt to reduce
observer effect.

Methods and design
Study organization
Forty-five subjects were randomly assigned to one of three
groups by a predetermined three-way randomization chart:
a “functional DA group” (Group 1) consisting of 20 participants
who were given fully functioning DA devices with visual and
audible alarms as dosing reminders and drop usage recording
turned on (Alcon Laboratories, Inc., Fort Worth, TX, USA);
a “no DA alarms group” (Group 2) consisting of 20 participants
who were given DAs with disabled visual and audible alarms
but that still monitored drop usage (ie, silent monitors); and
a “nonfunctional DA group” (Group 3) consisting of five
participants given nonfunctioning, placebo devices with
visual and audible alarms disabled, and monitoring disabled.
Subjects were informed that not all patients would be monitored. Groups 2 and 3 were given devices without audible
or visual alarms to introduce doubt as to whether or not they
were being monitored. All subjects were told at baseline that
some of the devices were nonfunctional. Thus, the patients
in Groups 2 and 3 were masked to whether or not they were
being monitored on dose usage.
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Patient study involvement
All subjects were given travoprost medication and trained
on how to place the travoprost bottle in the DA and how to
depress the lever arm to deliver a drop. Subjects were told
that, when functioning, the device records usage when the
lever is depressed. Subjects were asked to specify a 2-hour
window during which they intended to use the medication
each evening for which the functional DAs were set to trigger alarms. The subjects were supplied with free medication
during the study period. Subjects returned in 6 weeks and the
information was downloaded from each device and compiled
in an identity-masked database. The subjects filled out a brief,
non-validated six-item questionnaire on their perceptions of
the device, including whether or not they believed their own
device was functional. The questionnaire was intended to
help us gain some potential insight into subjects’ behaviors
and perceptions after utilization of the DA.

Subjects and eligibility criteria
A total of 45 subjects were included, 20 in each monitored
group and five in the unmonitored group. Inclusion criteria
allowed for subjects with any type of glaucoma or glaucoma
suspect diagnoses, treated with one or more glaucoma medications that included a topical prostaglandin analog. The number
of patients chosen for each group was based on how many
patients were interested in participating who fit the eligibility
criteria for the duration of the study. The main exclusion criteria were mental and physical disabilities of subjects, including
poor vision, precluding usage of the device and medication
adherence. Patients were also excluded if they were unable to
understand the study, if they did not instill their own drops, or
if they were incapable of using the DA after a brief demonstration. All eligible patients had to be 18 years of age or older.
The study was reviewed by the Sidney Kimmel Medical
College Institutional Review Board and deemed in concordance with the provisions of the Declaration of Helsinki and
was registered in the NIH public database. Written informed
consent was obtained.

DA
The DA can provide data only on use of the topical prostaglandin analog travoprost, because no other bottles for
glaucoma medications fit within it. A bottle of travoprost
is placed in the device and a lever is used to squeeze out a
drop. A built-in memory chip records the time and date when
the lever is depressed. The DA also has visual and audible
reminders that can be set to remind patients to take their drops
in a specified time period daily. Data can be downloaded to
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assess whether or not a patient adhered to drop usage on a
given day.1 Because the device has the potential to make
extra recordings when the lever is depressed accidentally,
eg, if more than one dose is used to ensure instillation within
the eye, more than one dose taken per eye per day was not
counted in the adherence rate calculation (travoprost is
indicated for once-daily use). When the lever was depressed
outside the time window, it was assumed that a dose was not
taken, and when the lever was depressed multiple times in
the time window, only a single dose was assumed to have
been delivered.10

were recruited, more than half of which were on travoprost
monotherapy prior to the study, the others were changed to
travoprost for the study (Table 1). All but one (who died)
completed the questionnaire. In the “functional DA group”
one device malfunctioned. In the “no DA alarms group”, two
devices were never returned despite persistent attempts to
obtain these, and three devices malfunctioned. The malfunctioning devices showed no data recorded after the first day,
and were returned to the manufacturer (Alcon Laboratories,
Inc.) who was also unable to retrieve data from these or to
determine the reason for the absence of data.

Outcome measures

Patient adherence

The primary outcome was medication adherence, defined as
any use of eyedrops on a given day. The secondary outcome
was awareness of monitoring. Medication adherence was
based on the DA data and secondary questionnaire. This
questionnaire was an instrument created for this study with
no previous validity evidence, with adherence rated using
a single yes/no question. The survey implemented patient
awareness of monitoring as a second self-report measure that
was documented by either a yes or no to each question.

Overall average medication adherence, defined as taking the
eyedrops on a given day, was 78% of doses (95% confidence
interval [CI]: 71%–85%). Adherence was nearly identical in
both groups: 78% adherence in the “functional DA group”
(95% CI: 70%–88%) and 76% adherence in the “no DA
alarms group” (95% CI: 65–89). The relative risk of adherence comparing the “functional DA group” to “no DA alarms
group” was 1.03 with a 95% CI of 0.85, 1.25 (P=0.76). In
case reduced adherence over time in both groups was a factor,
the first 15 days of therapy were assessed. Results differed
slightly when considering only the first 15 days of data for
each subject. The adherence for the first 15 days was 81%
(95% CI: 74–89). Adherence did not significantly (statistically) differ between groups. There was 85% adherence
in the “functional DA group” (95% CI: 78–93) and 76%
adherence in the “no DA alarms group” (95% CI: 64–91).
The relative risk of adherence comparing these two groups
was 1.11 (95% CI of 0.91–1.36) (P=0.29). The functional

Statistical analysis
Poisson regression with robust standard errors was used
to model the relative risk of adherence while accounting
for correlation among multiple measurements from the
same subject. A first-order autoregressive structure was
assumed for the working correlation structure.11,12 Logistic
regression analysis was used to test for association between
questionnaire response and adherence. The group to which
subjects were assigned and their questionnaire responses
were assessed and included as covariates in the logistic
regression model to determine whether there was an association. Exact chi-square tests were used to look for differences
among groups with respect to questionnaire responses. In a
sensitivity analysis, both sets of models were repeated using
only the first 15 days of follow-up to ensure equal amounts
of data for each subject because some subjects did not
complete the 6-week course. In this way, we also examined
both adherence and short-term persistence. All analyses
were performed using SAS version 9.1 (SAS Institute Inc.,
Cary, NC, USA).

Results
Baseline characteristics
Forty-five subjects (age: 67.6 years [standard deviation:
12.1]; 47% male) with a variety of glaucoma diagnoses
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Table 1 Study group characteristics
Characteristics

Functional No DA
DA group alarms group
(Group 1) (Group 2)

Male/female patients 8/12
68.15±12.77
Age in years:
mean ± SD
Race: AA, C, A
6, 13, 1
POAG
11
Number of medications
Only 1
9
Two
6
Three
5
Dropout reasons
1 died

Nonfunctional
DA group
(Group 3)

9/11
66.26±11.1

4/1
66.8±14.62

8, 11, 1
11

3, 1, 1
2

17
2
1
3 device
malfunctions,
2 devices unable
to recover data

1
2
2
none

Abbreviations: SD, standard deviation; AA, African American; C, Caucasian;
A, Asian; POAG, primary open angle glaucoma; DA, Travoprost Dosing Aid.
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DA group had slightly but nonsignificantly higher adherence
than the no DA alarms group.
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Adherence within a 2-hour window
of the time of planned dosing
Another planned evaluation was use of the medication
within an hour before or after subject’s chosen time of
dosage. Overall adherence within this window was 42%
(95% CI: 34–54). Adherence within 2 hours was higher in the
fully functional group than in the no alarms group: 51%; (95%
CI: 40–65) vs 31% (95% CI: 20–48), although the difference was not statistically significant (P.0.05). The relative
risk of adherence within 2 hours was 1.63 (95% CI: 1–2.68)
(P=0.052). In the first 15 days, adherence within a 2-hour
window of the planned dosage was 43% (95% CI: 33–56) for
all groups together. Again, adherence was higher in the
fully functional group (55%; 95% CI: 42–73) than in the
alarms only group (29%; 95% CI: 18–47). The relative
risk was 1.89 favoring greater adherence in the first group
(95% CI: 1.08–3.30 [P=0.025]). These data suggest that the
group with functional visible and audible alarms were more
timely in their dosing in the first 15 days of the study.

Actual and self-reported medication
adherence
Subjects in the “no DA alarms group” were more likely to
admit to not administering eyedrops and were much less
likely to agree that the DA affected how much they used
their drops (see Table 2, questions 1 and 4). In Group 1, the
“functional DA group”, 95% of subjects reported missing
less than one drop per week on average, but the DA recordings showed only 30% to have missed less than one drop per
week. For Group 2, the “no DA alarms group”, these numbers
were 68% by self-report and 30% by DA.
Participants in the “nonfunctional DA group” were less
likely to think that their DA was functioning (40%), although

the difference was not statistically significant (P=0.20), and
most patients in the other two groups felt that they were
being monitored (80% and 74%). Eighty percent of subjects
in Group 3 felt the DA affected their drop use, which was
statistically significant compared to the other two groups.

Patient adherence and the
questionnaire responses
The increased adherence in patients who believed that they
were being monitored was not statistically significant. There
was no association between questionnaire response and
adherence (see Table 3: odds ratios greater than 1 indicate
that adherence was higher for those patients answering “yes”
to the questions, while odds ratios less than 1 indicate that
adherence was higher for patients answering “no” to the questions). The only statistically significant association was that
patients in the “no DA alarms group” had a slightly higher
odds ratio of adherence if they reported that using the DA
affected how much they used their drops.

Discussion
It was initially hypothesized that adherence rates would be
different in each group, depending on the modifications made
to the DA and whether, as a result, a patient would feel as
if he or she was being monitored. Adherence was not statistically different between the “functional DA group” with
functioning visible and audible dosing alarm reminders, and
the “no DA alarms group”. A similar percentage of patients
suspected they were being monitored in both of these groups
despite that those in Group 2 were given a DA that had no
alarm reminders for the subjects. This supports that even
without reminder alarms, subjects still adhered in a similar
fashion to those with the reminder alarms. This, along with
the questionnaire, substantiates that altering the presence
of reminders on the DA did not significantly reduce subject
perceptions of being observed/monitored.

Table 2 Association of group membership and questionnaire response
Question

Number (%) with positive response

1. Are you missing more than one drop per week on average?
2. Do you like the DA?
3. Do you feel as if you were monitored by the DA?
4. Did the DA affect your drop use?
5. Would you recommend the DA?
6. Would you continue to use the DA?

Group 1
(n=20)

Group 2
(n=19)

Group 3
(n=5)

P-value for exact
chi-square test of
differences among
three groups

1 (5)
17 (85)
16 (80)
10 (50)
17 (85)
16 (80)

6 (32)
14 (74)
14 (74)
4 (21)
14 (74)
14 (74)

0 (0)
5 (100)
2 (40)
4 (80)
5 (100)
5 (100)

0.056
0.35
0.20
0.029
0.35
0.45

Notes: Group 1: fully functional; Group 2: no alarms; Group 3: nonfunctional.
Abbreviation: DA, Travoprost Dosing Aid.
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Table 3 Association between responses to questionnaire and adherence by group
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Question

1. Are you missing more than one
drop per week on average
2. Do you like the DA?
3. Do you feel as if you were
monitored by the DA?
4. Do you feel that the DA affected
your drop use?
5. Would you recommend the DA?
6. Would you continue using the DA?

Group

1
2
1
2
1
2
1
2
1
2
1
2

Odds ratio
(adherence vs no
adherence –
yes vs no)

95% confidence interval
Lower

Upper

1.11
0.57
2.11
1.95
1.77
4.97
1.33
3.07
2.11
1.95
2.11
1.95

0.62
0.28
0.42
0.39
0.46
0.71
0.45
1.10
0.42
0.39
0.42
0.39

1.97
1.16
10.59
9.79
6.91
34.78
3.88
8.59
10.59
9.79
10.59
9.79

P-value

0.73
0.12
0.36
0.42
0.41
0.11
0.60
0.03
0.36
0.42
0.36
0.42

Notes: Group 1 (n=19): functional DA; Group 2 (n=15): no DA alarms.
Abbreviation: DA, Travoprost Dosing Aid.

According to the questionnaire, 74% of patients in
Group 2 and 40% of patients in Group 3 felt they were being
monitored (Table 2). Group 3 had a significant increase in
medication adherence if they indicated that the DA improved
their dose usage, though their DAs were nonfunctional. It
appears that there was insufficient doubt about the monitoring process among subjects, despite their being informed at
baseline that some subjects would not be monitored. Actions
such as turning off the visual and audible DA alarms or
providing nonfunctional devices did not affect subjects’
perception of monitoring.

Lessons learned
This trial showed relationships between subject perception
of monitoring and medication usage, an observer effect.
Clinical trial results may be biased because subjects alter their
behavior when they are monitored. In addition, patients’ selfselection bias to enroll may also affect study results. These
aspects should be considered when applying results to clinical
practice. These issues have affected this study, despite efforts
to convince subjects that they were not being monitored. This
raises the possibility that a favorable outcome in a clinical
trial may not directly translate into a favorable outcome for
a patient in unobserved, “real” clinical practice.
Another significant finding is the difference in self-reported
adherence by questionnaire compared to actual adherence as
recorded by the DA. For instance, 95% of Group 1 subjects
indicated that they had not missed more than one drop on
average, per week, while the DA indicated that this actually only was true for 30% of these subjects. It would be
interesting for additional studies to explore the difference in

Patient Preference and Adherence 2016:10

self-reported adherence vs actual adherence and to assess in
which populations those differences are the largest.
In previous studies, patients reported far higher medication use than their actual behavior. Several reasons have been
suggested for this, including patients wanting to please their
physicians, patients not wanting to admit an error, or patients
not feeling comfortable enough to admit their concerns
with the medication.9 Reported levels of non-adherence are
affected by environmental cues and the method of questioning. Patient self-report and DA data produced different
estimates of adherence in the current study and the self-report
numbers for adherence were higher.
Although patient adherence can be assessed by indirect
means (ie, interviewing, assessing pharmacy records), each
of these has limitations. Electronic monitoring may be more
accurate than any other option, but is also limited in that
patients who know they are being monitored may change
their behaviors as a result of the Hawthorne effect.13,14
Although subjects were aware for the entire study period
that they may have been monitored, many clinical trials have
actually found poor adherence despite patients’ knowledge
of monitoring, and often any effects that may be attributed to
monitoring reactivity are transient. This could be explored in
a study that follows patient adherence over a longer period
of time than this study, to see if once subjects became accustomed to being monitored, they act naturally.13,14
Interestingly, searches for other observation trials found
behavioral studies of police that suggested that observation
influences behavior but that over time this influence diminishes. This may be because the research subjects become
accustomed to the observer and begin to act naturally. While
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clearly a different situation, this may explain the drop-off
in adherence over a longer period of time. The similarity
between the groups independent of time may be due to the
fact that all of them, as indicated in the questionnaire, felt
monitored to some extent.13–15

Limitations
The limitations of this study primarily were the small population sizes in each randomized group and that not all of the
dosing aids were returned or able to provide the necessary
information regarding dose usage. It was also a limitation
to assess a 2-hour window of adherence and it would be
interesting to see if a larger window correlated better with
patient perception and adherence. Additionally, there was no
true non-monitored comparison group in this study, because
all participants believed it was possible that their daily
medication use was monitored. It would be worth repeating the study under conditions where the DA is not also the
method for collecting adherence data: if pharmacy fill data
were available as the measure of adherence, some patients
were also given a DA, and others were not. The confounding of the adherence measure with the monitoring device is
a design problem that the current study could not solve. The
self-report measure was a single, unvalidated item and more
well-validated adherence self-report tools might produce
different results. This study utilized the 2-hour window of
patient adherence and questionnaire, but future studies may
benefit by exploring additional metrics to assess adherence,
such as other self-reported measures (such as the visual
analog scale), or collecting the DA bottles and looking at
the amount of medication left over.

Conclusion
It is both difficult and important to experiment with study
designs that mitigate bias induced by artificial circumstances
within a trial to achieve results that will reflect real clinical
practice. This study suggests that the biases introduced by
inclusion in a study may overwhelm deliberate attempts to
induce doubt about observation.
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